Diabetes Mellitus Prevalence in HIV Patients on Antiretroviral Therapy at Parirenyatwa Group of Hospitals Opportunistic Infections Clinic, Harare, Zimbabwe

Download Article

DOI: 10.21522/TIJPH.2013.05.01.Art017

Authors : Pasipanodya Ian Machingura, Adam Chindore


HIV patients have increased life expectancy due to the access to antiretroviral drugs treatment. However the increasing age comes with increased risk to non communicable diseases which include diabetes mellitus. However the prevalence of diabetes mellitus amongst HIV patients has not been extensively studied in Zimbabwe. Thus we sought to determine the prevalence of diabetes mellitus amongst HIV patients on antiretroviral therapy treatment attending Parirenyatwa Group of Hospitals Opportunistic Infections Clinic, Harare, Zimbabwe.

A cross-sectional study was conducted at Parirenyatwa Group of Hospitals Opportunistic Infections Clinic, Harare, Zimbabwe. All HIV patients (18 years and older) on antiretroviral therapy attending Parirenyatwa Group of Hospitals Opportunistic Infections Clinic during the study period were given information on the study. Only those who consented to participate in the study were recruited. Demographic data was obtained from patients by administration of questionnaires. Blood samples were collected for glycosylated haemoglobin analysis on a Mispa-i2 Chemistry Analyser.

A total of 60 HIV patients on antiretroviral therapy were recruited into the study, 33 (55%) were females and 27 (45%) were males. The mean age was 43.48 ± 10.3 years. Majority of the patients (33.3%) were on tenofovir, lamivudine and efavirenz. The prevalence of diabetes mellitus was 8.3%.

Diabetes mellitus prevalence amongst the HIV patients on antiretroviral therapy treatment was 8.3%. There is need for need to investigate the factors associated with diabetes mellitus in HIV patients on antiretroviral therapy treatment and confirm the prevalence in a study with a large sample size.

Keywords: Human Immunodeficiency Syndrome, antiretroviral therapy, diabetes mellitus


[1]. Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS. Effect of nonnucleoside reverse transcriptase inhibitor–based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. JAIDS J Acquir Immune DeficSyndr. 2011; 57 (4):284–9.

[2]. Gebreyesus HA. Prevalence of prediabetes in HIV-1 infected adults receiving antiretroviral therapy in Addis Ababa, Ethiopia. Int J PharmaSci Res. 2015; 6 (2):440–3.

[3]. Haregu TN, Olenburg B, Setswe G, Elliott J, Nanayakkara V. Epidemiology of Comorbidity of HIV/AIDS and Non-­communicable Diseases in Developing Countries: A systematic review. J Glob Health Care Syst. 2012; 2 (1).

[4]. Mohammed AE, Yemane Shenkute T, ChenekeGebisa W. Diabetes mellitus and risk factors in human immunodeficiency virus-infected individuals at Jimma University Specialized Hospital, Southwest Ethiopia. Diabetes MetabSyndrObes Targets Ther. 2015 Apr; 197.

[5]. Maganga E, Smart LR, Kalluvya S, Kataraihya JB, Saleh AM, Obeid L, et al. Glucose Metabolism Disorders, HIV and Antiretroviral Therapy among Tanzanian Adults. Pacheco AG, editor. PLOS ONE. 2015 Aug 19; 10(8):e0134410.

[6]. Manning K, Senekal M, Harbron J. Non-communicable disease risk factors and treatment preference of obese patients in Cape Town. Afr J Prim Health Care Fam Med. 2016; 8(1):1–12.

[7]. Monroe AK, Glesby MJ, Brown TT. Diagnosing and Managing Diabetes in HIV-Infected Patients: Current Concepts. Clin Infect Dis. 2015 Feb 1; 60 (3):453–62.

[8]. Moyo D, Tanthuma G, Mushisha O, Kwadiba G, Chikuse F, Cary MS, et al. Diabetes mellitus in HIV-infected patients receiving antiretroviral therapy. SAMJ South Afr Med J. 2014; 104 (1):40–2.

[9]. Rasmussen LD, Mathiesen ER, Kronborg G, Pedersen C, Gerstoft J, Obel N. Risk of Diabetes Mellitus in Persons with and without HIV: A Danish Nationwide Population-Based Cohort Study. Atashili J, editor. PLoS ONE. 2012 Sep 12; 7 (9):e44575.

[10]. Shen Y, Wang Z, Liu L, Zhang R, Zheng Y, Lu H. Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China. BMC Infect Dis. 2013; 13 (1):79.

[11]. The International Expert Committee. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009 Jul 1; 32 (7):1327–34.

[12]. World Health Organization. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. 2011 [cited 2016 Oct 28]; Available from: http://apps.who.int/iris/handle/10665/70523